RSS Feeds
Successful Treatment of Hypoglycemia Using Glucagon in a Patient with an Extrapancreatic Tumor
- Naguib A. Samaan, MD, PhD;
- Frank K. Pham, BS;
- Rena V. Sellin, MD;
- Jose F. Fernandez, MD; and
- Robert S. Benjamin, MD
Excerpt
The mechanism of hypoglycemia in extrapancreatic tumors remains controversial, and no treatment has been established. Some investigators have suggested that the hypoglycemia may, in part, be the result of growth-hormone deficiency and, if so, that treatment with growth hormone might be beneficial (1-3). This theory, however, has not been tested. We recently had the opportunity to evaluate both the mechanism of and the treatment options for hypoglycemia in a patient with a severe case resulting in meningeal sarcoma with retroperitoneal and liver metastases. We found that although growth-hormone deficiency was present, growth-hormone treatment was not effective; continuous intravenous glucagon administration,
This 100-word excerpt has been provided in the absence of an abstract.
Article and Author Information
-
From the University of Texas M. D. Anderson Cancer Center, Houston, Texas. For current author addresses, see end of text.
-
Grant Support: By the Nancy D. Carmichael Estate for Cancer Research and the Robert V. Davidson Estate for Cancer Research, Houston, Texas.
-
Requests for Reprints: Naguib A. Samaan, MD, PhD, Chief, Section of Endocrinology, Box 15, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.
-
Current Author Addresses: Drs. Samaan, Sellin, and Fernandez, and Mr. Pham: Section of Endocrinology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.
Dr. Benjamin: Department of Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.
